Full Press Release Details
BEYONTTRA (acoramidis), The First Near Complete TTR Stabilizer (≥90%), Approved By The European Commission For ATTR-CM.
BBIO
BEYONTTRA (acoramidis), The First Near Complete TTR Stabilizer (≥90%), Approved By The European Commission For ATTR-CM
Key Takeaway: BEYONTTRA (acoramidis), The First Near Complete TTR Stabilizer (≥90%), Approved By The European Commission For ATTR-CM
Price reaction · baseline $31.76 (2025-02-10 close) · hit after-hours · 1 other BBIO headline(s) in the window, move may be shared
day 0 close · peak
-2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis